Microviable Therapeutics announced the appointment of Dr. Luis Gosálbez as a member of its Business Advisory Board. Gosálbez brings 10 years of experience in business strategy and corporate development for life sciences companies specialized in microbiome and probiotics industry, with additional extensive experience in regulatory affairs.
“Luis’ experience overseeing business strategy, market access and regulatory intelligence in previous biotech organizations, with strong expertise on microbiome industry, provides him a unique and broad perspective of this emerging field where microbiome-derived products are being developed as novel biological drugs”, said Claudio Hidalgo, Ph.D., co-founder and Chief Executive Officer of Microviable Therapeutics. “We are excited to welcome Luis Gosálbez on board as strategic advisor and look forward to his contributions.”
Luis Gosálbez held different roles as business development, innovation and strategy executive at Clasado Biosciences, OptiBiotix Health and Biopolis, establishing corporate alliances, business strategy and commercial launch. Since 2018 he is the co-founder and Managing Director of Sandwalk Bioventures, an end-to-end innovation, strategy, regulatory intelligence and management consulting firm specialized in microbiome technologies. Gosálbez earned his MBA in from the University of Cambridge, his PhD in Life Sciences from UCAM, his M.Sc. in Biotechnology and B.Sc. in Biology from Universidad Complutense de Madrid.
“Microviable has strength its development platform for complete microbiota ecosystem products and bacterial consortia, and I am thrilled to join at this growth stage contributing to stablish its leadership position on the microbiome industry and advance their lead candidate into clinical trials”, said Luis Gosálbez.
